924309-93-3

Basic information

• Product Name: 2-acetaMidonon-8-enoic acid
• Synonyms: 2-acetaMidonon-8-enoic acid;8-Nonenoic acid, 2-(acetylaMino)-
• CAS NO: 924309-93-3
• Molecular Formula: C11H19NO3
• Molecular Weight: 213.27346
• EINECS: -0
• Mol File: 924309-93-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-acetaMidonon-8-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-acetaMidonon-8-enoic acid(924309-93-3)
• EPA Substance Registry System: 2-acetaMidonon-8-enoic acid(924309-93-3)

Safety Data

• Hazardous Substances Data: 924309-93-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Acetamidonon-8-enoic acid is used as an anti-inflammatory and analgesic agent for its ability to inhibit COX activity, leading to a reduction in inflammation and pain.
Used in Neurodegenerative Disease Treatment:
2-Acetamidonon-8-enoic acid is used as a potential neuroprotective agent for its antioxidant properties, which may help in the treatment of neurodegenerative diseases by protecting neurons from oxidative stress and damage. Further research is needed to fully understand its therapeutic applications in this area.

Upstream product

• 929-21-5 7-chloro-1-heptene 
• 4117-09-3 7-bromo-hept-1-ene 

Downstream Products

• 924307-76-6 (S)-2-amino-8-nonenoic acid 
• 1058705-94-4 N-tert-butoxycarbonyl-2-amino-8-nonenoic acid dicyclohexylamine salt 

Relevant articles and documents

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

Efficient synthesis of (S)-2-(cyclopentyloxycarbonyl)-amino-8-nonenoic acid: Key building block for BILN 2061, an HCV NS3 protease inhibitor

A new procedure for the practical synthesis of (S)-2-(cyclopen- tyloxycarbonyl)amino-8-nonenoic acid, a key building block for BILN 2061, an HCV NS3 protease inhibitor, has been developed. The key step features a kinetic resolution of racemic 2-acetylamino-8-nonenoic acid with acylase I. In addition, the undesired (R)-2-acetylamino-8-nonenoic acid was recycled after racemization. The procedure was implemented for the production of (S)-2-(cyclopentyloxycarbonyl)amino-8-nonenoic acid on pilot-plant scale.